Skip to main content
Premium Trial:

Request an Annual Quote

KineMed, Bristol-Myers Squibb Extend Collaboration on Alzheimer's Biomarkers


Proteomics firm KineMed and Bristol-Myers Squibb have extended their collaboration on Alzheimer's and other neurodegenerative diseases, KineMed said this week.

Under the extension, KineMed will grant BMS a non-exclusive license to its technology for the identification and characterization of Alzheimer's biomarkers in cerebrospinal fluid.

The companies didn't identify what biomarkers they would be investigating, but much of KineMed's past Alzheimer's work has focused on monitoring changes in microtubule dynamics by measuring related CSF biomarkers. The company's platform uses stable isotope labeling with mass spectrometry to measure the rates of change in various disease-related metabolic pathways.

In the June 2010 edition of Neuroscience KineMed scientists published a study tracking turnover levels of the protein tubulin in brain microtubule populations that suggested that changes in microtubule turnover can be used as a biomarker for the synaptic plasticity involved in memory formation.

Financial and other terms of the deal were not disclosed.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.